By Shakthi T Bhaskar, Bhagirathbhai Dholaria & 3 more. Since the first (CAR) T-cell product received FDA approval in 2017, studies have been completed that have led to approvals of CAR T-cells to treat a variety of malignancies.
No takes yet. Share an insight, caveat, or question.
Bhaskar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: